Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (711-720 of 754) with videos related to

Pageof 76
Sort By:
European Journal of Heart Failure|December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HFXiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
JACC. Heart Failure|June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary TrialsMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
BMC Medicine|November 11, 2016
Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiativesJoão Pedro Ferreira, Nicolas Girerd, Pierpaolo Pellicori, et al.
Frontiers in Digital Health|November 7, 2022
Considerations in the reliability and fairness audits of predictive models for advance care planningJonathan Lu, Amelia Sattler, Samantha Wang, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The New England Journal of Medicine|April 1, 2014
Survival with cardiac-resynchronization therapy in mild heart failureIlan Goldenberg, Valentina Kutyifa, Helmut U Klein, et al.
The New England Journal of Medicine|April 11, 2014
Spironolactone for heart failure with preserved ejection fractionBertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
Pageof 76

Showing results (711-720 of 754) with videos related to

Sort By:
Pageof 76
European Journal of Heart Failure|December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HFXiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
JACC. Heart Failure|June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary TrialsMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
BMC Medicine|November 11, 2016
Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiativesJoão Pedro Ferreira, Nicolas Girerd, Pierpaolo Pellicori, et al.
Frontiers in Digital Health|November 7, 2022
Considerations in the reliability and fairness audits of predictive models for advance care planningJonathan Lu, Amelia Sattler, Samantha Wang, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The New England Journal of Medicine|April 1, 2014
Survival with cardiac-resynchronization therapy in mild heart failureIlan Goldenberg, Valentina Kutyifa, Helmut U Klein, et al.
The New England Journal of Medicine|April 11, 2014
Spironolactone for heart failure with preserved ejection fractionBertram Pitt, Marc A Pfeffer, Susan F Assmann, et al.
Pageof 76